



2020/09/01

Company:	CYBERDYNE Inc.
Name of Representative:	Yoshiyuki Sankai, President and CEO
Code:	7779 (Mothers Section of the Tokyo Stock Exchange)
Contact:	Shinji Uga, Director and CFO (Tel. +81-29-869-9981)

**Registration of Medical HAL Lower Limb Type trial closed
~ The clinical trial scheduled for completion at December 2020~**

An investigator-initiated clinical trial for its HAL for Medical Use Lower Limb Type Single-leg Model, a product made by CYBERDYNE Inc. [Tsukuba, Ibaraki, CEO: Yoshiyuki Sankai (the “Company”)] is currently in progress, and the investigator announced that the clinical trial reached its target number of patients that is necessary for analysis and ne registration are closed. The trial is scheduled to be complete on December 2020.

The clinical trial started on September 2016, utilizing the research fund provided from Japan Agency for Medical Research and Development (“AMED”). The trial is designed as an investigator-initiated clinical trial, led by the lead investigator, University of Tsukuba Hospital and total of 16 hospitals all around Japan.

Reference link

https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000028545